ONESOURCE Onesource Specialty Pharma Q3 FY26 results (Oct–Dec 2025) and concall
OneSource Specialty Pharma Limited reported a challenging Q3 FY26 with a 26% YoY revenue decline to INR 2,903 million and an adjusted PAT loss of INR 472 million, primarily due to deferred semaglutide approvals in Canada. Despite near-term softness expected, the company reiterated its FY28 guidance of $400 million revenue and $160 million EBITDA, driven by expanding order books, new customer wins in biologics, and strategic capacity expansions. The company also achieved credit rating upgrades, reducing its cost of debt.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 26.2%, net profit down 29.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 393 | 426 | 327 | 376 | 290 −26% |
| EBITDA | 142 | 183 | 88 | 106 | 17 −88% |
| Net profit | -69 | 98 | 0 | 10 | -89 −29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
